DOCSLIB.ORG

Illumina RNA Prep with Enrichment a Fast, Integrated Workflow for RNA Enrichment Applications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Design Content | Prepare Library | Sequence | Analyze Data Illumina RNA Prep with Enrichment A fast, integrated workflow for RNA enrichment applications. Highlights First- and second-strand cDNA synthesis • Fast and simple RNA enrichment workflow Prepare libraries in as little as nine hours with less than two cDNA hours of hands-on time • Exceptional data quality from difficult samples Achieve high sensitivity from as little as 10 ng total RNA from eBLTLeBLT eBLTL Tagmentation fresh or frozen samples or 20 ng total RNA from degraded FFPE samples Enrichment Bead-Linked cDNA cDNA-eBLT-L complex Transposome (eBLTL) • Focused and affordable RNA sequencing Tagment with eBLTL Maximize discovery power with robust capture efficiency at reduced sequencing depth for accurate, unbiased detection Tagmented library • Flexible and scalable throughput Index PCR primers p5 Multiplex up to 384 samples in a single run with unique dual Index2 Read 1 sequencing primer (Rd1 SP) indexes Read 2 sequencing primer (Rd2 SP) Index1 p7 Index PCR Introduction p5 Index2 Rd1 SP Rd2 SP Index1 p7 Indexed library RNA sequencing (RNA-Seq) with next-generation sequencing (NGS) Pool pre-enriched libraries (optional) is a powerful method for discovering, profiling, and quantifying RNA transcripts. Advantages of RNA-Seq include: Pooled sample library • Targeted RNA-Seq analyzes expression in a focused set of Add biotinylated probe panel genes. Enrichment enables cost-effective RNA exome analysis using sequence-specific capture of the coding regions of the transcriptome. It is ideal for low-quality, formalin-fixed paraffin- embedded (FFPE) samples. Enrich using streptavidin magnetic beads • Total RNA-Seq provides an unbiased, hypothesis-free approach for comprehensive analysis of the transcriptome. It accurately measures gene and transcript abundance and detects both known and novel features in coding and multiple forms of noncoding RNA. Enriched library • Messenger RNA (mRNA)-Seq sensitively and accurately quantifies Elute enriched library from beads gene expression, identifies known and novel isoforms in the coding Enriched and indexed library ready for sequencing transcriptome and measures allele-specific expression. Figure 1: Illumina RNA Prep with Enrichment chemistry—After cDNA Illumina RNA Prep with Enrichment, (L) Tagmentation offers a synthesis, a uniform tagmentation reaction mediated by eBLT-Ls followed by a streamlined solution for targeted RNA-Seq. It offers high flexibility single, 90-minute hybridization reaction enables a fast and flexible workflow. regarding input type and amount to provide a wide range of RNA-Seq applications, enabling detection and discovery studies such as allele- enrichment Bead-Linked Transposomes (eBLT) optimized for RNA specific expression, fusion detection, biomarker screening, and more. (eBLTL) that mediate a uniform tagmentation reaction, eliminating Combining Illumina RNA Prep with Enrichment with the Illumina Exome the need for separate fragmentation steps to save time. Combined Panel provides a comprehensive view of the coding transcriptome for with innovations to the hybridization reaction, the workflow features maximum discovery power at a fraction of the sequencing depth. fewer steps, shorter incubation times, and numerous safe stopping points and a total assay time that is > 50% faster than TruSeq™ RNA Fast and simple RNA enrichment workflow Exome (Figure 2). In addition to manual preparation, Illumina RNA Prep with Enrichment is designed to be compatible with liquid-handling Illumina RNA Prep with Enrichment uses On-Bead Tagmentation platforms for an automated workflow, providing highly reproducible followed by a simplified, single 90-minute hybridization step to provide sample handling, reduced risk of human error, and less hands-on time. a rapid workflow (Figure 1). On-Bead Tagmentation features For Research Use Only. Not for use with diagnostic procedures. 470-2020-001-A | 1 Design Content | Prepare Library | Sequence | Analyze Data TruSeq RNA Exome Illumina RNA Prep with Enrichment 10000 1 RNA quantitation 1 RNA quantitation and qualication and qualication Fragmentation is not required 2 2 RNA fragmentation 2 cDNA synthesis 1000 R = 0.99 3 cDNA synthesis 3 Tagmentation using BLT chemistry 100 4 A-tailing 4 PCR, quantication, and normalization 10 5 Ligation less than 9 hours 5 Single, 90 min enrichment Capture, washes, and elution PCR, quantication, and UHR, 100 ng input 6 6 PCR amplication of 0 normalization enriched library more than 2 days more 7 First enrichment 7 Quantication and Capture, washes, and elution normalization 0.1 8 Second enrichment 8 Ready for sequencing Capture, washes, and elution 0.1 0 10 100 1000 10000 9 PCR amplication of UHR, 10 ng input enriched library > 50% decrease in 10 Quantication and total assay time normalization Figure 3: High-quality data from low input samples—Illumina RNA Prep with 11 Ready for sequencing Enrichment achieves high data concordance between input amounts of 10 ng and 100 ng total RNA from universal human reference (UHR). UHR RNA libraries were sequenced on a NovaSeq 6000 System, subsampled to 25M clusters per Figure 2: Illumina RNA Prep with Enrichment delivers a fast workflow— library. Data was analyzed with the BaseSpace RNA-Seq Alignment v 1.1.1 app. On-Bead Tagmentation and a single, 90-minute hybridization step combine to deliver a faster workflow with fewer steps compared to TruSeq RNA Exome. chr22 chr9 High-quality data chr22:23,629,909-23,639,668 chr9:133,724,597-133,734,356 Highly accurate data from low-input and FFPE samples [0 - 913] [0 - 913] U1_K562...overage High capture efficiency and coverage uniformity minimize the required U1_K562_10ng_Lot2_CE sequencing depth to determine expression levels accuratelyX_1plex_Rep125M.alig and without bias. Starting with as little as 10 ng total RNA,nments.bam Illumina RNA Prep with Enrichment produces quality data with high concordance [0 - 134] [0 - 134] U1_K562...overage between varying amounts of input RNA from fresh or frozen samples (Figure 3). Precious tumor–normal specimens or FFPEU1_K562_10ng_Lot2_CE archival tissue samples provide a rich source of biological informationX_1plex_Rep125M.alig for gene nments.SA.bam expression profiling; however, they can be difficult to study due to nucleic acid degradation from the fixation and storageSequence process.1 RefSeq Genes Illumina RNA Prep with Enrichment produces quality data with BCR ABL1 input as low as 20ng of input RNA from FFPE samples. Together, these results demonstrate that Illumina RNA Prep with Enrichment Figure 4: Detection of BCR-ABL1 gene fusion—Libraries prepared from 10 ng is an ideal solution for precious or degraded samples with limited K-562 cell line RNA using Illumina RNA Prep with Enrichment and the Illumina Exome Panel resulted in successful detection of the BCR-ABL1 gene fusion, starting material. using the Broad Integrative Genomics Viewer (IGV). Top alignment track shows all reads; bottom track shows only reads supporting the BCR-ABL1 fusion. Gene fusion detection in low-input and FFPE samples To demonstrate the ability of Illumina RNA Prep with Enrichment to Table 1: Gene fusion detection recognize structural variants within RNA transcripts, fresh/frozen RNA Fusion (source) RIN Detection and FFPE samples were enriched using the Illumina Exome Panel input ™ and sequenced using the NovaSeq 6000 System. Results showed BCR-ABL1 (K-562) 7.4 10 ng 6/6 replicates (100%) a 100% call rate for BCR-ABL1 (Figure 4) and TPM3-NTRK1 gene TPM3-NTRK1 (colorectal cancer) 2.5 20 ng 6/6 replicates (100%) fusions across six replicates of the K-562 cell line (RNA integrity number, RIN = 7.4, DV200 = 90%) and a colorectal cancer cell line (RIN = 2.5, DV200 = 85%), respectively (Table 1). 2 | 470-2020-001-A For Research Use Only. Not for use with diagnostic procedures. Design Content | Prepare Library | Sequence | Analyze Data Focused, affordable RNA-Seq Illumina RNA Prep with Enrichment UHR Exceptional exonic coverage FFPE Illumina RNA Prep with Enrichment can be used with the Illumina Exome Panel, which features a highly optimized probe set that delivers TruSeq RNA Exome comprehensive coverage of coding RNA sequences (Table 2). UHR Table 2: Illumina Exome Panel specifications FFPE Coverage specification Illumina Exome Panel No. of target genes 21,415 0% 25% 50% 75% 100% No. of target exonic regions 214,126 % Bases aligned to region No. of probes 425,437 RefSeq exome percent covered 98.3% Coding UTR Intron Intergenic To evaluate the performance of Illumina RNA Prep with Enrichment Figure 6: Coverage of coding regions with Illumina RNA Prep with for exome sequencing, libraries were prepared from universal human Enrichment—Libraries prepared from 10 ng UHR RNA and 20 ng FFPE RNA reference (UHR) RNA and FFPE RNA using Illumina RNA Prep with using Illumina RNA Prep with Enrichment and the Illumina Exome Panel show Enrichment. Resulting libraries were sequenced on a NovaSeq 6000 more than 85% of the data aligned to coding and UTRs. Data from TruSeq RNA Exome libraries are shown for comparison. Libraries were sequenced on a System at 2 × 100 bp (25 M reads). Data analysis with the Enrichment NovaSeq 6000 System at 2 × 100 bp, subsampled to 25 M reads. App in BaseSpace™ Sequence Hub revealed that Illumina RNA Prep with Enrichment resulted exceptional exonic coverage (Figure 5) with > 85% of the bases covered aligning to coding sequence and Concordance with TruSeq RNA Exome untranslated regions (UTR) of RNA, comparable to TruSeq RNA Comparison of data generated
Recommended publications
  • Next-Gen Sequencing Identifies Non-Coding Variation Disrupting

    Next-Gen Sequencing Identifies Non-Coding Variation Disrupting

    OPEN Molecular Psychiatry (2018) 23, 1375–1384 www.nature.com/mp ORIGINAL ARTICLE Next-gen sequencing identifies non-coding variation disrupting miRNA-binding sites in neurological disorders P Devanna1, XS Chen2,JHo1,2, D Gajewski1, SD Smith3, A Gialluisi2,4, C Francks2,5, SE Fisher2,5, DF Newbury6,7 and SC Vernes1,5 Understanding the genetic factors underlying neurodevelopmental and neuropsychiatric disorders is a major challenge given their prevalence and potential severity for quality of life. While large-scale genomic screens have made major advances in this area, for many disorders the genetic underpinnings are complex and poorly understood. To date the field has focused predominantly on protein coding variation, but given the importance of tightly controlled gene expression for normal brain development and disorder, variation that affects non-coding regulatory regions of the genome is likely to play an important role in these phenotypes. Herein we show the importance of 3 prime untranslated region (3'UTR) non-coding regulatory variants across neurodevelopmental and neuropsychiatric disorders. We devised a pipeline for identifying and functionally validating putatively pathogenic variants from next generation sequencing (NGS) data. We applied this pipeline to a cohort of children with severe specific language impairment (SLI) and identified a functional, SLI-associated variant affecting gene regulation in cells and post-mortem human brain. This variant and the affected gene (ARHGEF39) represent new putative risk factors for SLI. Furthermore, we identified 3′UTR regulatory variants across autism, schizophrenia and bipolar disorder NGS cohorts demonstrating their impact on neurodevelopmental and neuropsychiatric disorders. Our findings show the importance of investigating non-coding regulatory variants when determining risk factors contributing to neurodevelopmental and neuropsychiatric disorders.
  • Whole Exome and Whole Genome Sequencing

    Whole Exome and Whole Genome Sequencing

    UnitedHealthcare® Community Plan Medical Policy Whole Exome and Whole Genome Sequencing Policy Number: CS150.J Effective Date: October 1, 2021 Instructions for Use Table of Contents Page Related Community Plan Policies Application ..................................................................................... 1 • Chromosome Microarray Testing (Non-Oncology Coverage Rationale ....................................................................... 1 Conditions) Definitions ...................................................................................... 2 • Molecular Oncology Testing for Cancer Diagnosis, Applicable Codes .......................................................................... 3 Prognosis, and Treatment Decisions Description of Services ................................................................. 4 • Preimplantation Genetic Testing Clinical Evidence ........................................................................... 4 U.S. Food and Drug Administration ........................................... 22 Commercial Policy References ................................................................................... 22 • Whole Exome and Whole Genome Sequencing Policy History/Revision Information ........................................... 26 Medicare Advantage Coverage Summaries Instructions for Use ..................................................................... 26 • Genetic Testing • Laboratory Tests and Services Application This Medical Policy does not apply to the states listed below; refer to
  • Clinical Exome Sequencing Tip Sheet – Medicare Item Numbers 73358/73359

    Clinical Exome Sequencing Tip Sheet – Medicare Item Numbers 73358/73359

    Clinical exome sequencing Tip sheet – Medicare item numbers 73358/73359 Glossary Chromosome microarray (CMA or molecular Monogenic conditions (as opposed karyotype): CMA has a Medicare item number to polygenic or multifactorial conditions) are for patients presenting with intellectual caused by variants in a single gene. Variants disability, developmental delay, autism, or at may be inherited (dominant or recessive least two congenital anomalies. CMA is the fashion), or may occur spontaneously (de recommended first line test in these cases as novo) showing no family history. it can exclude a chromosome cause of disease which is unlikely to be detected by Whole exome sequence – sequencing only exome. the protein coding genes (exons). The exome is ~2% of the genome and contains ~85% of Gene panel is a set of genes that are known to disease-causing gene variants. be associated with a phenotype or disorder. They help narrow down the search Whole genome sequence – sequencing the for variants of interest to genes with evidence entire genome (all genes, including coding linking them to particular phenotypes and noncoding regions) Human phenotype ontology (HPO) terms Singleton – Analysis of the child only. describe a phenotypic abnormality using a Trio – analysis of the child and both biological standard nomenclature. Ideally, all clinicians parents. and scientists are using the same terms. Variant - A change in the DNA code that Mendeliome refers to the ~5,000 genes (out of differs from a reference genome. about 20,000 protein coding genes) that are known to be associated with monogenic disease. As variants in new genes are identified with evidence linking them with human disease, they are added to the Mendeliome.
  • The Genomics Era: the Future of Genetics in Medicine - Glossary

    The Genomics Era: the Future of Genetics in Medicine - Glossary

    The Genomics Era: the Future of Genetics in Medicine - Glossary The glossary below provides a list of key terms used throughout the course. You do not need to read them all now; we’ll be linking back to the main glossary step wherever these terms appear, so you may refer back to this list if you are unsure of the terminology being used. Term Definition The process of matching reads back to their original Alignment position in the reference genome. An allele is one of a number of alternative forms of the same gene or genetic locus. We inherit one copy Allele of our genetic code from our mother and one copy of our genetic code from our father. Each copy is known as an allele. Microarray based genomic comparative hybridisation. This is a technique used to detect chromosome imbalances by comparing patient and control DNA and comparing differences between the two sets. It is Array CGH a useful technique for detecting small chromosome deletions and duplications which would not have been detected with more traditional karyotyping techniques. A unit of DNA. There are four bases which form the Base cross links (or rungs) of the DNA double helix: adenine (A), thymine (T), guanine (G) and cytosine (C). Capture see Target enrichment. The process by which a cell becomes specialized in Cell differentiation order to perform a specific function. Centromere The point at which the sister chromatids are joined. #1 FutureLearn A structure located in the nucleus all living cells, comprised of DNA bound around proteins called histones. The normal number of chromosomes in each Chromosome human cell nucleus is 46 and is composed of 22 pairs of autosomes and a pair of sex chromosomes which determine gender: males have an X and a Y chromosome whilst females have two X chromosomes.
  • Whole Exome Sequencing (WES)

    Whole Exome Sequencing (WES)

    Whole Exome Sequencing (WES) Turn Around Time: 30 Days TEST METHODOLOGY CPT Codes: Proband – 81415, Family Member – 81416 DNA will be extracted from whole blood or Test Includes: DNA Extraction other specimen types. Extracted DNA is Library Prep quantified and sheared to the correct size. The Exome Capture sample then undergoes library preparation and Library QC the exome is captured. After quality assurance, Illumina Platform Sequencing the captured library is then subjected to next Data Analysis generation DNA sequencing on the Illumina Sanger Variant Confirmation (if requested) platform. The reads from this sequencing are Interpreted Clinical Report aligned to a reference sequence and variations from this reference are identified. The sequence variants are then loaded into a commercial software package that contains data sources and Expedited WES testing is available. algorithms allowing for the evaluation of whole Contact the lab for more information. exome sequencing variants for evolutionary conservation, predicted impact on protein TEST DESCRIPTION structure and function (including Polyphen2 (5) and SIFT (6)), ability to disrupt conserved Whole Exome Sequencing (WES) is used to detect variants in a patient’s exome splice sites, and presence in databases including in order to determine the role of genomic variants in disease outcomes. The OMIM, dbSNP, and HGMD (1,2,3). The exome is a little more than 1% of the genome that codes for protein. The patient’s software annotates variants with this data, exome will be sequenced to an average depth of 100X with a minimum depth of considering both the reference gene model and coverage of 85X. Over 97% of the exome will be sequenced to a depth of 10X.
  • Genomic Technologies for Cancer Research

    Genomic Technologies for Cancer Research

    Genomic Technologies for Cancer Research www.illumina.com/applications/cancer.html Table of Contents I. Introduction: Genomic Technologies for Cancer Research 3 II. Approaches for Detecting Somatic Mutations 4 Targeted Sequencing Solutions for Somatic Mutation Detection 4 Exome Sequencing 4 Focused Sequencing Panels 4 Custom Targeted Sequencing 4 Whole-Genome Sequencing Solutions 4 Data Analysis Tools for Somatic Variant Detection 5 III. Evaluating Germline Mutations in Cancer 6 Targeted Sequencing to Detect Common Germline Mutations 7 Microarray-Based Approaches 7 IV. Structural Variant Detection in Cancer 7 DNA and RNA Sequencing for Translocation Detection 8 Copy Number Variation Arrays 8 V. Investigating Gene Regulation in Cancer 8 DNA–Protein Interactions 8 DNA Methylation 9 RNA Sequencing 9 Targeted RNA Sequencing 9 Small RNA Sequencing 10 Data Analysis Tools for the Study of Gene Regulation 11 VI. Summary 11 For Research Use Only. Not for use in diagnostic procedures. I. Introduction: Genomic Technologies for Cancer Research In recent years, genomic technologies have emerged as invaluable tools in cancer research (Figure 1). International projects such as the International Cancer Genome Consortium (ICGC)1 and The Cancer Genome Atlas (TCGA)2, tasked with mapping the biology of dozens of tumor types, would not have been possible without these tools. Next-generation sequencing (NGS) and high-density microarrays are used to study the biology of cancer. Both provide the cancer research community with a growing body of knowledge that may lead to more effective drug design, better patient treatment options, and more accurate prognoses.3 Normal Neoplastic Changes Tumor Treatment Response Recurrence PROGRESSION Somatic Mutations Germline Gene Expression & Mutations Epigenetic Changes Additional Mutations Chromosomal Abnormalities HETEROGENEITY Figure 1: The Tumor Progression Pathway—Genomic technologies are helping researchers achieve a deeper understanding of the tumor progression pathway.
  • RNA Next Generation Sequencing Resources Available at the Experimental and Computational Genomics Core (ECGC)

    RNA Next Generation Sequencing Resources Available at the Experimental and Computational Genomics Core (ECGC)

    RNA next generation sequencing resources available at the Experimental and Computational Genomics Core (ECGC) Kornel Schuebel, PhD ECGC Resource Director [email protected] Telephone 410-614-0445 CRB2 Rm 131 (lab) CRB2 Rm 1m44 (office) What’s our mission? To facilitate easy access to genomic technologies and bioinformatics expertise, including experimental design, sample processing, and data analysis. To build educational and training opportunities for genomics analysis. Next Generation Microarray Sequencing Experimental and Computational Genomics Biostatistics and Genomics Bioinformatics Education Analysis The ECGC team Faculty Directors Staff Leslie Cope Michael Considine Sarah Wheelan Anuj Gupta Vasan Yegnasubramanian Jennifer Meyers Alyza Skaist Resource Director Hai Xu Kornel Schuebel Coordinators Lauren Ciotti Luda Danilova Daniel Vellucci Core faculty IT support Rob Scharpf Greg Smith Elana Fertig Dominic King How do I start my project? Let us know a little (a Lauren Sarah sentence or two is fine) Vasan Contact us at ecgc.jhmi.edu about your project Leslie Kornel Schedule and attend a consultation Lauren Meet with us to establish an Sarah experimental plan, discuss Vasan costs and a timeline Leslie Set up an iLab project report Kornel and drop off samples Drop off times are generally Lauren on Tuesdays and Thursdays Jennifer Kornel We will contact you to verify types of data analysis you want Anuj, Alyza, Michael Schedule a meeting to look We confirm with you the Sarah comparisons your iLabs Vasan at the data together report showed
  • Guide to Interpreting Genomic Reports: a Genomics Toolkit

    Guide to Interpreting Genomic Reports: a Genomics Toolkit

    Guide to Interpreting Genomic Reports: A Genomics Toolkit A guide to genomic test results for non-genetics providers Created by the Practitioner Education Working Group of the Clinical Sequencing Exploratory Research (CSER) Consortium Genomic Report Toolkit Authors Kelly East, MS, CGC, Wendy Chung MD, PhD, Kate Foreman, MS, CGC, Mari Gilmore, MS, CGC, Michele Gornick, PhD, Lucia Hindorff, PhD, Tia Kauffman, MPH, Donna Messersmith , PhD, Cindy Prows, MSN, APRN, CNS, Elena Stoffel, MD, Joon-Ho Yu, MPh, PhD and Sharon Plon, MD, PhD About this resource This resource was created by a team of genomic testing experts. It is designed to help non-geneticist healthcare providers to understand genomic medicine and genome sequencing. The CSER Consortium1 is an NIH-funded group exploring genomic testing in clinical settings. Acknowledgements This work was conducted as part of the Clinical Sequencing Exploratory Research (CSER) Consortium, grants U01 HG006485, U01 HG006485, U01 HG006546, U01 HG006492, UM1 HG007301, UM1 HG007292, UM1 HG006508, U01 HG006487, U01 HG006507, R01 HG006618, and U01 HG007307. Special thanks to Alexandria Wyatt and Hugo O’Campo for graphic design and layout, Jill Pope for technical editing, and the entire CSER Practitioner Education Working Group for their time, energy, and support in developing this resource. Contents 1 Introduction and Overview ................................................................ 3 2 Diagnostic Results Related to Patient Symptoms: Pathogenic and Likely Pathogenic Variants . 8 3 Uncertain Results
  • Examples of How ENCODE Facilitates Biomedical Research

    Examples of How ENCODE Facilitates Biomedical Research

    Examples of how ENCODE facilitates biomedical research ENCODE Users Meeting Potomac, MD Richard M. Myers [email protected] July 1, 2015 http://www.hudsonalpha.org/ Richard M. Myers Disclosure Our group has been part of the ENCODE Consortium since it began in 2003 Rick Myers Barbara Wold Ross Hardison pasdfasdf Eric Mendenhall Ali Mortazavi Tim Reddy Richard M. Myers 2 Goals of ENCODE Annotate the human genome Disseminate data to researchers everywhere Richard M. Myers 3 5 examples of how we use ENCODE data to help in our research on human diseases Richard M. Myers 4 1. Discovering the causes of undiagnosed genetic diseases Richard M. Myers 5 Childhood genetic disorders 1.5-3% of kids worldwide are born with 1 or more of: • intellectual disability • developmental delay • heart defects • craniofacial and skeletal abnormalities • severe autism • seizures The vast majority of these problems have genetic causes Richard M. Myers 6 Diagnostic challenges for childhood genetic disorders Inaccurate or undetermined causes (i.e., diagnoses) are a major hardship: Years of expensive, invasive, and futile testing Impossible to predict disease progression, symptoms Treatment decisions are complicated Slows research into developing new therapies Impacts family planning Results in feelings of parental guilt and lack of control Thus, identifying the root genetic causes is essential Richard M. Myers 7 HudsonAlpha Pediatric Genetics Project Sequence whole genomes of 500 children with developmental/ intellectual delay of unknown etiology (and both parents’ genomes too) North Alabama Univ. of Louisville Children’s Specialists HudsonAlpha Richard M. Myers 8 Exome results so far Exome sequencing completed for 171 families Definitive genetic diagnosis in 25% of the children Pitt-Hopkins syndrome Dravet syndrome Rett syndrome Rubinstein-Taybi syndrome Noonan-like syndrome Many never-described causes 25%25%! ! >20% of families receive uncertain genetic findings that 56%! will likely be definitively diagnostic in the future 56%! 19%19%! ! Richard M.
  • Combining Whole-Exome and RNA-Seq Data Improves the Quality of PDX Mutation Profiles

    Combining Whole-Exome and RNA-Seq Data Improves the Quality of PDX Mutation Profiles

    Combining whole-exome and RNA-Seq data improves the quality of PDX mutation profiles Manuel Landesfeind 1, Bruno Zeitouni 1, Anne-Lise Peille 1, Vincent Vuaroqueaux 1 1 Oncotest - Charles River, Am Flughafen 12-14, 79108 Freiburg, Germany 1 Introduction 2 Mutation profiling technologies and data analysis 3 Evaluation of WES mutation detection pipeline Patient-derived xenograft tumor models (PDX) are an important tool for anti- Materials: Methods: PDX-specific bioinformatics pipelines (Fig. 3) comprises mapping of • Mutation screening using Sequenom Oncocarta panels 1-3 paired-end reads to human and mouse reference genomes using BWA and cancer agent testing. Oncotest has developed a unique collection of models SEQUENCING DATA (FASTQ) QC • We investigated as reference data, 25 genes in 284 models Figure 4: Venn- WES targeting mutations in 39 genes, validation of mutations by TopHat for WES and RNA-Seq data respectively. Reads that map better to covering all major lineages (Fig. 1). In the context of targeted therapy containing 500 mutations assessed by Sanger sequencing diagram of 500 Sanger sequencing in 25 genes in 284 models mouse are removed. Human-specific duplicate reads are discarded. After base Read Mapping on Human Read Mapping on Mouse mutations from Sanger development, an accurate and comprehensive molecular characterization is • WES data for 300 models, DNA extraction using Agilent quality score recalibration, WES Variant detection is performed utilizing GATK- • Our WES analysis retrieved > 95% of these mutations (Fig. 4) hg19 genome mm10 genome Sanger and 988 crucial for model selection and for biomarker identification. We recently SureSelect All Human Exon kits (v1, v4, or v5) and Lite, Samtools, Freebayes.
  • Report 103356

    Report 103356

    Patient: DoB: 1 /10 Sample report as of Feb 1st, 2021. Regional differences may apply. For complete and up-to-date test methodology description, please see your report in Nucleus online portal. Accreditation and certification information available at blueprintgenetics.com/certifications Whole Exome Plus REFERRING HEALTHCARE PROFESSIONAL NAME HOSPITAL PATIENT NAME DOB AGE GENDER ORDER ID 1 Male PRIMARY SAMPLE TYPE SAMPLE COLLECTION DATE CUSTOMER SAMPLE ID SUMMARY OF RESULTS PRIMARY FINDINGS Analysis of whole exome sequence variants in previously established disease genes The patient is heterozygous for MPZ c.532del, p.(Val178Trpfs*74), which is likely pathogenic. Del/Dup (CNV) analysis Negative. SECONDARY FINDINGS The patient is heterozygous for PMS2 c.1297A>T, p.(Lys433*), which is likely pathogenic. Please see APPENDIX 3: Secondary Findings for further details PRIMARY FINDINGS: SEQUENCE ALTERATIONS IN ESTABLISHED DISEASE GENES GENE TRANSCRIPT NOMENCLATURE GENOTYPE CONSEQUENCE INHERITANCE CLASSIFICATION MPZ NM_000530.7 c.532del, p.(Val178Trpfs*74) HET frameshift_variant AD Likely pathogenic ASSEMBLY POS REF/ALT ID GRCh37/hg19 1:161276170 AC/A PHENOTYPE gnomAD AC/AN POLYPHEN SIFT MUTTASTER Charcot-Marie-Tooth disease, 0/0 N/A N/A N/A Dejerine-Sottas disease SEQUENCING PERFORMANCE METRICS SAMPLE MEDIAN COVERAGE PERCENT >= 20X Index 162 99.25 Blueprint Genetics Oy, Keilaranta 16 A-B, 02150 Espoo, Finland 1 / 10 VAT number: FI22307900, CLIA ID Number: 99D2092375, CAP Number: 9257331 Patient: DoB: 2 / 10 TEST INFORMATION Blueprint Genetics Whole Exome Plus Test (version 2, Feb 9, 2018) consists of sequence analysis of all protein coding genes in the genome for the proband, coupled with Whole Exome Deletion/Duplication (CNV) Analysis.
  • Whole Exome and Transcriptome Sequencing Solutions for Solid Tumor and Hematological Cancers

    Whole Exome and Transcriptome Sequencing Solutions for Solid Tumor and Hematological Cancers

    Coming Sema4 Signal WES/WTS Soon Sema4 Signal PanCancer Whole exome and transcriptome sequencing solutions for solid tumor and hematological cancers We are excited to announce the upcoming launch of Sema4 Signal WES/WTS (~20,000 genes) and Sema4 Signal PanCancer (>2,000 cancer-related genes), two comprehensive testing solutions designed for all solid tumor and hematological malignancies. These advanced offerings integrate whole exome sequencing (WES), whole transcriptome sequencing (WTS), and tumor-normal matched analysis to deliver insights across both somatic and germline* mutations to help providers: Determine diagnoses and prognoses for solid tumor or hematological cancers Identify and use available targeted therapies Make decisions regarding suitability of current clinical trials Learn about certain hereditary contributions to various cancer types* Gain insight regarding secondary findings per ACMG guidelines** (with consent) Powerful insights to help personalize cancer treatment Our tumor-normal matched DNA analysis and RNA-seq (tumor only) analysis cover these alterations and features based on 250x tumor coverage and 100x normal coverage across all genes, and 100M RNA reads: • Single nucleotide variants (SNVs) • Insertion/Deletions (INDELs) • Copy number variants (CNVs) • Fusions • Certain splice variants • Tumor mutational burden (TMB) • Microsatellite instability (MSI) • Arm- and chromosome-level aneuploidies Samples accepted: FFPE Fresh frozen Bone marrow Blood Saliva Buccal swab * Please note that while some inherited genetic changes may be detected, these tests do not replace comprehensive germline testing. If an inherited condition is suspected in the patient or their family member(s), a different test with the purpose of examining germline genetic changes based on family and/or personal history may be appropriate.